

# The CRISPR ancillary effector Can2 is a dual-specificity nuclease potentiating type III CRISPR defence

Wenlong Zhu<sup>†</sup>, Stuart McQuarrie<sup>†</sup>, Sabine Grüşchow, Stephen A. McMahon, Shirley Graham, Tracey M. Gloster\* and Malcolm F. White<sup>✉\*</sup>

Biomedical Sciences Research Complex, School of Biology, University of St Andrews, St Andrews KY16 9ST, UK

Received December 22, 2020; Revised January 22, 2021; Editorial Decision January 25, 2021; Accepted January 27, 2021

## ABSTRACT

Cells and organisms have a wide range of mechanisms to defend against infection by viruses and other mobile genetic elements (MGE). Type III CRISPR systems detect foreign RNA and typically generate cyclic oligoadenylate (cOA) second messengers that bind to ancillary proteins with CARF (CRISPR associated Rossman fold) domains. This results in the activation of fused effector domains for antiviral defence. The best characterised CARF family effectors are the Csm6/Csx1 ribonucleases and DNA nickase Can1. Here we investigate a widely distributed CARF family effector with a nuclease domain, which we name Can2 (CRISPR ancillary nuclease 2). Can2 is activated by cyclic tetra-adenylate (cA<sub>4</sub>) and displays both DNase and RNase activity, providing effective immunity against plasmid transformation and bacteriophage infection in *Escherichia coli*. The structure of Can2 in complex with cA<sub>4</sub> suggests a mechanism for the cA<sub>4</sub>-mediated activation of the enzyme, whereby an active site cleft is exposed on binding the activator. These findings extend our understanding of type III CRISPR cOA signalling and effector function.

## INTRODUCTION


CRISPR systems provide many bacteria and most archaea with adaptive immunity against mobile genetic elements (MGE) (1–3). They are divided into two distinct classes based on the composition of the effector modules. Class 1 systems (types I, III IV) use multi-subunit effector complexes. Class 2 systems consist of three subtypes (types II, V and VI) and their effector modules are single, large and multifunctional proteins (2).

Type III CRISPR systems are further divided into Csm (type III-A and III-D) and Cmr (type III-B and III-C) CRISPR systems (2). Their effector complexes are elaborate multi-functional proteins, targeting and cleaving foreign RNA via base-pairing with crRNA (4–6). Target RNA binding in turn can activate two further enzymatic activities within the complex: sequence-nonspecific single-stranded DNA degradation by an HD nuclease domain (7–9) and cyclic oligoadenylate (cOA) synthesis from ATP by a cyclase domain (10–12). In some type III systems, either one or the other of these active sites is absent or non-functional (13–15). cOA is an anti-viral second messenger that activates ancillary effector proteins to potentiate the immune response. To date, several dimeric Csx1/Csm6 family nucleases have been characterised as CRISPR ancillary proteins allosterically activated by cOA binding in the CRISPR associated Rossman fold (CARF) domain within Csx1/Csm6 (16–18). They function as non-specific RNases through their C-terminal HEPN (Higher Eukaryotes and Prokaryotes, Nucleotide binding) domains. *Sulfolobus islandicus* Csx1 forms a trimer of dimers and each dimer binds a cyclic tetra-adenylate (cA<sub>4</sub>) molecule, resulting in non-specific ssRNA cleavage by the C-terminal HEPN domain (16). Moreover, a novel CRISPR defence DNA endonuclease, Can1 (CRISPR ancillary nuclease 1) was identified in our previous study (19). Can1 has a unique monomeric structure with two non-identical CARF domains (Figure 1A). Upon cA<sub>4</sub> binding in the CARF domain, Can1 rapidly nicks supercoiled DNA non-specifically followed by slower DNA degradation *in vitro* through its C-terminal metal-dependent nuclease domain. Notably, another DNA endonuclease, NucC, is activated by a cyclic tri-nucleotide molecule in response to bacteriophage infection in CBASS (cyclic oligonucleotide-based anti-phage signalling systems) (20,21). NucC homologues have also been identified in association with type III CRISPR systems where they are assumed to be regulated by cyclic tri-adenylate (cA<sub>3</sub>) generated by the Cas10 subunit (20).

\*To whom correspondence should be addressed. Tel: +44 1334 463432; Email: mfw2@st-andrews.ac.uk

Correspondence may also be addressed to Tracey M. Gloster. Tel: +44 1334 467245; Email: tmg@st-andrews.ac.uk

<sup>†</sup>The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.



**Figure 1.** Genome context and domain organisation of Can2. (A) Domain organisation of Can1 and Can2. Each has an N-terminal CARF domain and a C-terminal PD-ExK superfamily nuclease domain. The *can1* gene has been predicted to arise from a gene duplication of *can2* (19) and includes Domain 2 – a divergent inactive nuclease domain. The *can2* gene numbering is from *S. thermosulfidooxidans*. (B) Gene organisation of selected CRISPR type III systems that include a *can2* gene. Can2 is found associated with both type III-A (Csm) and type III-B (Cmr) systems, and frequently with other CARF family effector proteins. A common neighbouring gene encodes the Crn2 ring nuclease for degradation of cA<sub>4</sub> (27). Genes labelled as ‘CARF’ encode uncharacterised CARF family proteins. Genes are coloured consistently across the different genomes. Species represented are *Sulfobacillus thermosulfidooxidans* (Sth), *Thioalkalivibrio sulfidiphilus* (Tsu), *Nitrococcus mobilis*, *Haemophilus haemolyticus* and *Methylomagnum ishizawai*.

Although cOA synthesis is shut off after target RNA cleavage and dissociation from the type III effector complex, activated CRISPR ancillary proteins continue to degrade both viral and cellular nucleic acid (10,22), suggesting that a mechanism for cOA removal might be required. Recently, novel groups of CARF domain proteins, named CRISPR associated ring nuclease 1 (Crn1) (23) and Crn3 (24) were identified, which are dedicated to degrading cA<sub>4</sub>. Moreover, some Csm6 proteins are able to degrade their own cOA activator using their CARF domains (17,18,25). Therefore, various catalytic activities of CARF domain family proteins play important roles in the immune response against MGEs for bacteria and archaea.

In our previous study, we analysed the structure and mechanism of the CARF domain family protein Can1 (19). By comparing the structure of the two halves of Can1 with the DUF1887 family protein VC1899 (PDB: 1XMX) from *Vibrio cholerae*, we postulated that Can1 was derived from an ancestral DUF1887 protein by gene duplication, fusion and subsequent divergent evolution (19). Given the relationship with Can1, DUF1887 family members consisting of a single N-terminal CARF domain fused to a C-terminal nuclease domain will be referred to hereafter as Can2 (CRISPR ancillary nuclease 2). *can2* is much more widely distributed throughout the bacterial phyla than *can1*, particularly in the firmicutes and proteobacteria, and is typically associated with type III CRISPR systems. A selection of type III CRISPR loci incorporating *can2* genes is shown in Figure 1B. *can2* is found in association with genes encoding CARF-family proteins known or predicted to bind cOA (26), and in one case the nuclease NucC. Genes encoding

the ring nuclease Crn2, which degrades cA<sub>4</sub> to deactivate the defence system (27), are found adjacent to *can2* in some genomes, and in others *crn2* is replaced by the uncharacterised *csx16* gene, implicating the latter as a potential ring nuclease (28).

Here, we describe the structure and mechanism of the Can2 protein. We show that Can2 is a metal dependent nuclease, non-specifically degrading both supercoiled DNA and ssRNA, once activated by cA<sub>4</sub> binding. We co-crystallized Can2 with cA<sub>4</sub> and solved the structure to 2.0 Å resolution, revealing its detailed molecular architecture and mechanism of activation. Furthermore, we demonstrate that Can2 confers immunity in a reconstituted CRISPR system in *Escherichia coli* by interfering with phage infection.

## MATERIALS AND METHODS

### Cloning

For cloning, synthetic genes (g-blocks) encoding SthCan2, TsuCan2 and VC1899 (full sequences are shown in Supplementary Table S1), codon optimised for expression in *Escherichia coli*, were purchased from Integrated DNA Technologies (IDT), Coralville, USA and cloned into the pE-HisV5TEV vector between the NcoI and BamHI sites (29). Competent DH5α (*E. coli*) cells were transformed with the construct and sequence integrity was confirmed by sequencing (GATC Biotech, Eurofins Genomics, DE). The plasmids were then transformed into *E. coli* C43 (DE3) cells for protein expression. The inactivated nuclease domain variants, E276A/D278A for SthCan2, E302A/K304A for TsuCan2 and E291A/D293A for VC1899 were expressed from

plasmids where the QuikChange Site-Directed Mutagenesis kit was used to introduce mutations in the wild type genes as per manufacturer's instructions (Agilent Technologies; primers used for mutagenesis are shown in Supplementary Table S2).

### Protein production and purification

For protein expression, the cells expressing each Can2 orthologue in LB medium were grown at 37°C to an OD<sub>600</sub> of ~0.8, and then expression was induced with 0.4 mM isopropyl-β-D-1-thiogalactoside (IPTG) and grown overnight at 25°C. Cells were harvested by centrifugation at 3063 × *g* at 4°C for 15 min and resuspended in buffer containing 50 mM Tris-HCl pH 7.5, 500 mM NaCl, 10 mM imidazole and 10% glycerol. A protease inhibitor tablet (Roche; one tablet per 100 ml) and lysozyme (Sigma-Aldrich; 1 mg/ml) were added to the cell suspension, and cells were lysed by sonicating six times for 1 min on ice with 1 min rest intervals. The lysate was cleared at 117 734 × *g* at 4°C for 45 min and loaded onto a pre-equilibrated 5 ml HisTrap FF crude column (GE Healthcare), washed with 5 column volumes (CV) of wash buffer containing 50 mM Tris-HCl pH 7.5, 500 mM NaCl, 30 mM imidazole and 10% glycerol and eluted with a step gradient (holding at 20% for 4 CV and 50% for 4 CV) of elution buffer containing 50 mM Tris-HCl pH 7.5, 500 mM NaCl, 500 mM imidazole and 10% glycerol. Can2-containing fractions were pooled and concentrated using a 10 kDa molecular mass cut-off centrifugal concentrator (Merck). Tobacco Etch Virus (TEV) protease (1 mg per 10 mg protein) was used to remove the polyhistidine affinity tag while dialysing in wash buffer overnight at room temperature. The protein was isolated from TEV protease by the HisTrap FF crude column. The unbound fraction was collected and buffer-exchanged into a buffer containing 50 mM MES pH 6.5 and 150 mM NaCl using a centrifugal concentrator. Can2 was further purified by size exclusion chromatography (S200 26/60; GE Healthcare) in buffer containing 50 mM MES pH 6.5 and 150 mM NaCl. After concentration, Can2 was aliquoted and frozen at -80°C. The three Can2 homologues, SthCan2, TsuCan2 and VC1899 were purified using the same method. Nuclease variants were purified by the same method as for the respective wild-type proteins.

For seleno-methionine labelled expression of SthCan2, the plasmid containing the *can2* gene was transformed into *E. coli* B834 (DE3) cells. Cells were grown in M9 minimal medium supplemented with Selenomethionine Nutrient Mix (Molecular Dimensions, Newmarket, Suffolk, UK) and 50 mg l<sup>-1</sup> (L)-selenomethionine (Acros Organics). The protein was purified by the same method described for native SthCan2.

### Plasmid cleavage assays

1.8 nM supercoiled pEV5HisTEV plasmid was incubated with SthCan2 (500 nM dimer; equivalent to 1 μM total protein as measured by absorbance at 280 nm) and its nuclease domain variant E276A/D278A (500 nM dimer) for the time indicated in Figure 2. Reactions were carried out at 50°C in 20 μl final reaction volume at pH 7.0 with the

buffer containing 20 mM HEPES, 100 mM NaCl and 1 mM EDTA supplemented with 1 μM cA<sub>4</sub> and 5 mM MnCl<sub>2</sub>. The standard migration positions for supercoiled, linear or open circle plasmid were ascertained from the incubation with buffer only, with BamHI (Thermo Scientific) or with nicking endonuclease Nt.BspQI (New England BioLabs), respectively. Control reactions included incubating plasmid without protein, MnCl<sub>2</sub> or cA<sub>4</sub>. For single-turnover kinetics experiments, triplicate experiments were carried by incubating SthCan2 (500 nM dimer) with plasmid substrate (1.8 nM) under the same conditions and stopped at the indicated times by adding 10 mM EDTA. All reactions were analysed by 0.7% agarose gel electrophoresis. Gels were scanned and quantified as described previously (19). Nicked and linearized plasmids are considered as products. This value is divided by the total of products plus substrates, to give the fraction cleaved. The data were plotted against time using Kaleidagraph (Synergy Software) and fitted to a single exponential curve as previously described (19).


To test DNase activity of proteins VC1899 or TsuCan2, 1.8 nM plasmid was incubated with 500 nM dimer protein at 37°C or 50°C in 20 μl final volume in the same buffer as described above. Reactions were supplemented with 1 μM cA<sub>4</sub> and 5 mM MnCl<sub>2</sub> as indicated in Supplementary Figure S1. All reactions were stopped by adding 10 mM EDTA and analysed by 0.7% agarose gel electrophoresis.

### RNA cleavage assays

5'-FAM labelled ssRNA (30 nM) was incubated with SthCan2 (500 nM dimer) and E276A/D278A (500 nM dimer) for the desired time. The sequence of the ssRNA is listed in Supplementary Table S2. Reactions were carried out at 50°C in 20 μl final reaction volume in pH 7.0 buffer containing 20 mM HEPES, 100 mM NaCl, 1 mM EDTA and three units SUPERase•In Inhibitor (Thermo Scientific) supplemented with 1 μM cA<sub>4</sub> and 5 mM MnCl<sub>2</sub> or MgCl<sub>2</sub>. Control reactions included incubating RNA in buffer only, and incubating RNA without protein, metal ion or cA<sub>4</sub>. Experiments were carried out in triplicate for single-turnover kinetics and quenched by adding to five reaction volumes of phenol chloroform (Ambion) and vortexing. All reactions were analysed by 20% denaturing PAGE (20% acrylamide, 7 M urea and 1× Tris/borate/EDTA (TBE)). Gels were scanned and quantified as described previously (19). The uncleaved ssRNA at each time point was divided by the negative control to give the fraction uncleaved. The fraction cleaved was plotted against the time using Kaleidagraph (Synergy Software) and fitted to a single exponential curve as previously described (19). To test RNase activity of homologous proteins VC1899 or TsuCan1, reactions were carried out at 37°C in the same conditions.

### RNaseAlert fluorimetric assay

RNaseAlert substrates were purchased from Integrated DNA Technologies (IDT). 30 nM substrate was incubated with different enzymes (500 nM dimer) at 37°C for 35 min. Reactions were carried out in a 30 μl final reaction volume in a pH 7.0 buffer containing 20 mM HEPES, 100 mM NaCl, 1 mM EDTA and three units SUPERase•In



**Figure 2.** Can2 is activated by cA<sub>4</sub> to degrade scDNA and RNA. (A) Agarose gel analysis of supercoiled plasmid (1.8 nM) nicking and degrading activity by SthCan2 and TsuCan2 (500 nM dimer). Supercoiled plasmid was degraded rapidly by SthCan2 in the presence of cA<sub>4</sub> (1 μM) and MnCl<sub>2</sub> (5 mM). Plasmid was incubated with wild-type SthCan2 at 50 °C for 0.5, 1, 2 and 5 min in reaction buffer supplemented with cA<sub>4</sub> and MnCl<sub>2</sub>. The nuclease variant E276A/D278A was incubated under the same conditions for 30 min. Wild-type TsuCan2 and its nuclease variant E302A/K304A were incubated under the same conditions for 30 min at 37 or 50 °C. Standards corresponding to supercoiled (SC), linear and nicked plasmid are shown after the marker (M) lane. Control lanes C1, C2 and C3 show the reactions incubated for 30 min without protein, MnCl<sub>2</sub> and cA<sub>4</sub>, respectively. (B) Single-turnover kinetic analysis of scDNA cleavage by SthCan2 and Can1 (the plot for Can1 is from our previous study (19)). SthCan2 (500 nM dimer) was incubated with scDNA (1.8 nM) under the same conditions as in part A and the reaction was stopped at 10 s, 20 s, 40 s, 1 min, 2 min and 3 min. The cleaved fraction of scDNA was plotted against time and fitted to a single exponential curve as described in Materials and Methods. The rate constant of scDNA cleavage for SthCan2 and Can1 are  $3.39 \pm 0.57$  and  $0.81 \pm 0.15 \text{ min}^{-1}$ , respectively. Values and error bars represent the mean of triplicate experiments and the standard deviation. (C) Plot of fluorescent signals emitted by RNaseAlert substrates when they were cleaved by wild-type SthCan2, TsuCan2 or VC1899. RNaseAlert substrates (30 nM) were incubated with the enzymes (500 nM dimer) in reaction buffer and supplemented with cA<sub>4</sub> (1 μM) and MnCl<sub>2</sub> (5 mM) at 37 °C. The fluorescent signal was plotted against time. Values and error bars represent the mean of triplicate experiments and the standard deviation.

Inhibitor (Thermo Scientific), supplemented with 1 μM cA<sub>4</sub> and 5 mM MnCl<sub>2</sub>. The substrates are fluorescence-quenched oligonucleotide probes that emit fluorescence signal after being cleaved. The signal was detected using a microplate reader (FLUOstar Omega, BMG LABTECH) with excitation and emission wavelengths set at 485 and 520 nm, respectively.

### Radiolabelled cA<sub>4</sub> cleavage assays

<sup>32</sup>P labelled cA<sub>4</sub> was generated by incubating *S. solfataricus* type III-D complex with α-<sup>32</sup>P-ATP as described previously (30). For cA<sub>4</sub> cleavage assays, ~10 nM radiolabelled cA<sub>4</sub> was incubated with different concentrations of SthCan2. Reactions were carried out at 50 °C for 30 min in 20 μl final volume in 20 mM HEPES, 100 mM NaCl, 1 mM EDTA, pH 7.0 and three units SUPERase•In Inhibitor supplemented with 5 mM MgCl<sub>2</sub>. The control reaction was carried out by incubating radiolabelled cA<sub>4</sub> in buffer only under the same conditions. All reactions were quenched and deproteinized by phenol-chloroform extraction, then chloroform extraction, before loading onto thin-layer chromatography (TLC) plates. Plates were visualized by phosphor imaging.

### Plasmid ligation and supercoiling

1.5 nM pEV5HisTEV plasmid was incubated with SthCan2 (100 nM dimer) at 50 °C for 1.5 min in the pH 7.0 buffer described above, supplemented with 200 μM cA<sub>4</sub> and 5 mM MnCl<sub>2</sub>. Reactions were quenched and deproteinized by PCR Clean-Up System (Promega). The eluted product was incubated with DNA ligase and gyrase as described in a previous study (19). Nicking endonuclease Nt.BspQI was used as a positive control. All reactions were analysed by 0.7% agarose gel electrophoresis.

### Plasmid transformation assay

The construction of the pCsm1-5\_ΔCsm6 plasmid (containing the type III Csm interference genes *cas10* (*csm1*), *csm3*, *csm4*, *csm5* from *M. tuberculosis* and *csm2* from *M. canettii*) and pCsm1-5\_Cy plasmid expressing an inactivated cyclase variant (Csm1 D630A/D631A) of the Csm complex has been described previously (15,30). The cyclase variant is unable to synthesise cOA signalling molecules due to mutation of the cyclase domain (15,30). Plasmid pCRISPR\_TetR contains four identical spacers targeting the tetracycline-resistance gene and five repeats from *M. tu-*

*berculosis* (15,30). Plasmid pCRISPR which consists of two identical spacers targeting the pUC19 multiple cloning site (MCS) and three repeat sequences from *M. tuberculosis* was used for the 'Not targeting crRNA' control (15,30). Both plasmid pCRISPR\_TetR and pCRISPR contain *M. tuberculosis cas6*. Plasmid pRAT containing the tetracycline-resistance gene without insert (i.e. without effector gene) was used as the 'No Can2' control (15,30). Plasmid pRAT-Duet containing the tetracycline-resistance gene has been described previously (30). Plasmid pRAT\_TsuCan2 was constructed by cloning *can2* from *T. sulfidiphilus* into the 5'-NcoI and 3'-SalI sites of the pRAT-Duet MCS-1 vector by restriction digest. The plasmid transformation assay was carried out essentially as described previously (15,30). *E. coli* C43 (DE3) cells containing pCsm1-5\_ΔCsm6 and pCRISPR\_TetR were transformed by heat shock with 50 ng pRAT\_TsuCan2 or pRAT plasmid, indicated as 'Wild-type' or 'No Can2' in Figure 3A, respectively. *E. coli* cells containing pCsm1-5\_Cy and pCRISPR\_TetR were transformed with 50 ng of pRAT\_TsuCan2 plasmid indicated as 'Cyclase variant' in Figure 3A. *E. coli* C43 cells containing pCsm1-5\_ΔCsm6 and pCRISPR were transformed with 50 ng of pRAT\_TsuCan2 indicated as 'No targeting crRNA' in Figure 3A. After outgrowth at 37°C for 2.5 h, 5 μl of a 10-fold dilution series was applied onto LB agar containing 100 μg ml<sup>-1</sup> ampicillin and 50 μg ml<sup>-1</sup> spectinomycin to determine the cell density of the recipient cells and onto LB agar additionally containing 25 μg ml<sup>-1</sup> tetracycline, 0.2% (w/v) D-lactose and 0.2% (w/v) L-arabinose to determine the number of viable transformants. Plates were incubated at 37°C for 40 h. The experiment was carried out with two biological replicates and four experimental replicates each.

### Bacteriophage infection assay

A CRISPR array consisting of three identical spacers (Supplementary Table S2) targeting the *lpa* gene of bacteriophage P1 and four Mtb CRISPR repeats was ligated into the pCDFDuet<sup>TM</sup>-1 vector (Novagen, Merck Millipore) to give pCRISPR\_Lpa using the method described previously (15,30). *T. sulfidiphilus* (Tsu) *can2* was cloned into the pEV5HisTEV vector between the NcoI and BamHI sites, and the nuclease domain variant E302A/K304A was generated using the QuikChange Site-Directed Mutagenesis kit as per manufacturer's instructions (Agilent Technologies). Plasmid pRAT\_TsuCan2\_E302A/K304A was constructed by cloning the variant gene from this pEV5HisTEV construct into the 5'-NcoI, 3'-SalI sites of pRAT-Duet MCS-1.

Plasmids pCsm1-5\_ΔCsm6, pCRISPR\_Lpa and pRAT\_TsuCan2 were co-transformed into *E. coli* C43 (DE3) cells indicated as 'Wild-type' in Figure 3B. Plasmids pCsm1-5\_Cy, pCRISPR\_Lpa and pRAT\_TsuCan2 were co-transformed into *E. coli* cells and are indicated as 'Cyclase variant' in Figure 3B. Plasmids pCsm1-5\_ΔCsm6, pCRISPR and pRAT\_TsuCan2 were co-transformed into *E. coli* cells and are indicated as 'No Lpa target' in Figure 3B. Plasmids pCsm1-5\_ΔCsm6, pCRISPR\_Lpa and pRAT\_TsuCan2\_E302A/K304A were co-transformed into *E. coli* cells and are indicated as 'Can2 E302A/K304A' in Figure 3B. The cells were grown overnight at 37°C in LB broth containing 50 μg ml<sup>-1</sup> ampicillin, 25 μg ml<sup>-1</sup>

spectinomycin and 12.5 μg ml<sup>-1</sup> tetracycline. The overnight culture was diluted to OD<sub>600</sub> of ~0.1 (light path length: 10 mm) by LB broth supplemented with the antibiotics, 10 mM MgSO<sub>4</sub>, 0.2% (w/v) D-lactose and 0.2% (w/v) L-arabinose. 160 μl of diluted culture was infected with 40 μl bacteriophage P1 to give a MOI around 1 and was grown in a 96-well plate. The OD<sub>595</sub> of the culture in the plate (light path length: ~6.2 mm) was measured by a FilterMax F5 Multi-Mode Microplate Reader (Molecular Devices) every 15 min over 16 h incubation time. The experiment was carried out with four biological replicates and two technical replicates. The OD<sub>595</sub> was plotted against time over the 16 h incubation.

### Co-crystallisation of Can2 in complex with cA<sub>4</sub>


SthCan2 labelled with selenomethionine at 8 mg/ml was mixed with cA<sub>4</sub> such that the molar ratio of protein:cA<sub>4</sub> was 1:1. Crystallisation conditions were identified from the commercial screens JCSG and PACT 96 (Jena Biosciences). 75 μl of the mother liquor was added to the reservoir in a 96-well sitting drop plate, and the SthCan2 + cA<sub>4</sub> solution was mixed with mother liquor in a 0.45 μl drop with a 2:1 or 1:1 protein:mother liquor ratio. Plates were incubated at room temperature. Initial screens yielded optimal crystals in 20% (w/v) PEG 3350 and 0.2 M ammonium nitrate pH 6.3, which required no further optimisation prior to data collection. Crystals were harvested into a fresh 1 μl drop of mother liquor and 1 μl glycerol was added to the drop for cryo-protection. Crystals were mounted on loops and vitrified in liquid nitrogen.

### X-ray data processing, structure solution, and refinement

Data were collected at Diamond Light Source (DLS) on beamline I03 at a wavelength of 0.9790–2.02 Å resolution (data processing and refinement statistics are shown in Supplementary Table S3). Diffraction images were automatically processed through the Xia2 pipeline (31) using XDS (32) and AIMLESS (33). Phasing information and structure solution was done using the automated experimental phasing pipeline BigEP (34) at DLS, which used SHELX (35) to assess the quality of the anomalous signal and CRANK (36) for phasing and to build the initial model. REFMAC5 (37) and COOT (38) were used for refinement of the model, and addition of ligands and water molecules. The cA<sub>4</sub> ligand was drawn using Chemdraw (Perkin Elmer) and restraints generated in JLigand (39). Figures of the structures were created by CCP4mg (40) and PyMol (Schrödinger, LLC). The model was validated using tools in PDB-REDO (41) and Molprobity (42). The final Molprobity score is 1.2, centile 100, and Ramachandran statistics are 98.96% allowed, 0% disallowed. All structural alignment calculations were done using DALI (43). The coordinates and structure factors have been deposited in the Protein DataBank with accession code 7BDV.

### Statistics

Statistical analyses were performed with GraphPad Prism. Statistical significance was assessed as described for each experiment.



**Figure 3.** Can2 protects against MGE *in vivo*. (A) Plasmid challenge assay of mycobacterial type III-A system in *E. coli* host. *E. coli* cells harbouring the mycobacterial type III-A interference complex Csm1-5 and TetR targeting spacer were transformed with plasmid containing TsuCan2 effector and tetracycline-resistance gene (Wild-type). Other strains are indicated as ‘No Can2’ where the TsuCan2 is absent, ‘Cyclase variant’ where the interference complex is unable to produce cOA and ‘No targeting crRNA’ where the TetR targeting spacer is replaced with a spacer targeting pUC19 MCS. A 10-fold dilution series of the transformation mixture was applied onto tetracycline selective plates to determine the number of viable transformants. (B) Growth curves of *E. coli* cells harbouring the interference complex and phage P1 *lpa* gene-targeting spacer supplemented with TsuCan2 effector (indicated as Wild-type). Cells were grown in LB broth in a 96-well plate with shaking at 37°C and infected with phage P1 at a MOI of ~1. OD<sub>595</sub> of the culture was measured every 15 min to plot against time over the 16 h incubation. Other strains are indicated as ‘Cyclase variant’ (green) where the interference complex is unable to produce cOA molecules; ‘No Lpa target’ (black) where *lpa* gene-targeting spacer is replaced with a spacer targeting pUC19 (MCS); ‘Can2 E302A/K304A’ (grey) which is a TsuCan2 nuclease variant. ‘Control’ (purple) represents wild-type cells (orange) incubated without phage infection under the same conditions. Data points represent the mean of eight experimental replicates (four biological replicates with two technical replicates each) with the standard deviation shown. (C) The OD<sub>595</sub> values of all strains after 4 and 10 h growth are shown, coloured as in panel B. Statistical analysis was carried out with RStudio using the unpaired Welch two sample test to calculate *P*-values. NS (not significant) indicates *P*-values > 0.05 and \*\*\* indicates *P*-values < 1E-05.

## RESULTS

### Can2 is a cA<sub>4</sub> activated, metal dependent nuclease

To study the structure and mechanism of Can2, we expressed and purified the wild-type Can2 protein from the moderate thermophile *S. thermosulfidooxidans* (SthCan2) along with a E276A/D278A variant, targeting the C-terminal PD-ExK nuclease domain. Both enzymes were purified by immobilised metal affinity and gel filtration chromatography as described in the methods. Wild-type SthCan2 exhibited potent nuclease activity, degrading a supercoiled plasmid substrate (scDNA) after 5 min incubation in the presence of cA<sub>4</sub> and MnCl<sub>2</sub> at 50°C (Figure 2A). The majority of the plasmid was nicked within 1 min and after 5 min incubation most of the plasmid was linearized, with some degrading to smaller fragments. Reactions in the absence of Can2, MnCl<sub>2</sub> or cA<sub>4</sub> are shown in lanes C1, C2 and C3, respectively, in Figure 2A; they display very little activity, confirming that SthCan2 is a metal dependent nuclease activated by cA<sub>4</sub>. The rate of plasmid degradation for SthCan2 was determined under single turnover conditions, using 500 nM protein dimer incubated with 1.8 nM scDNA, as  $k_c = 3.4 \pm 0.57 \text{ min}^{-1}$  (Figure 2B) which was about 4-fold higher than the rate of the nickase Can1 under similar conditions (19). The E276A/D278A variant was inactive,

confirming that Can2 is a PD-ExK superfamily nuclease. This glutamate and aspartate residue form part of the highly conserved active site motif in PD-ExK nucleases, and if mutated abrogate activity. As observed previously for Can1, the nicked DNA products generated by SthCan2 were readily re-ligated by DNA ligase, consistent with generation of 3'-hydroxyl and 5'-phosphate ends (Supplementary Figure S2). Overall, the results suggest SthCan2 has cA<sub>4</sub>-activated DNA nickase activity, as observed previously for Can1 (19).

We also analysed a homologous protein from the mesophile *T. sulfidophilus* (TsuCan2). TsuCan2 and its nuclease variant E302A/K304A were incubated with scDNA under the same conditions at both 37 and 50°C (Figure 2A and Supplementary Figure S1B). Most scDNA was nicked after 30 min incubation only at 50°C, with markedly slower kinetics than for SthCan2. The E302A/K304A variant was inactive. Another homologue, VC1899 from *Vibrio cholerae*, was not able to nick or degrade scDNA after 30 min incubation at either 37 or 50°C (Supplementary Figure S1A and S1B).

We proceeded to test the RNase activity of the three proteins using the RNaseAlert fluorometric assay (Figure 2C). The substrates were fluorescence-quenched oligonucleotide probes that emit a fluorescent signal after being cleaved, and

have been used previously for studies of the Csm6 family enzymes (12,18). After 20 min incubation, the majority of RNaseAlert substrates were degraded by SthCan2 and TsuCan2. In contrast, VC1899 showed very little RNase activity. Controls in the absence of manganese or cA<sub>4</sub> activator confirmed that the RNase activity was metal and cA<sub>4</sub> dependent (Supplementary Figure S1C). Little or no RNase activity was observed among any nuclease variants (Supplementary Figure S1D). To confirm the RNase activity of Can2, we tested both enzymes in an assay with a fluorescent RNA substrate (Supplementary Figure S3). SthCan2 cleaved this RNA rapidly in the presence of Mn<sup>2+</sup>, with a rate constant in excess of 5 min<sup>-1</sup>, precluding accurate quantification. When the assays were repeated in the presence of Mg<sup>2+</sup>, the reaction rate was reduced allowing quantification of the RNA cleavage rate for SthCan2 as 1.2 ± 0.13 min<sup>-1</sup> (Supplementary Figure S3D).

Finally, we tested SthCan2 for the ability to degrade the cA<sub>4</sub> activator ('ring nuclease' activity) in the presence of Mg<sup>2+</sup> and observed that this activity was not present (Supplementary Figure S4), consistent with previous observations for Can1 (19). Recent studies suggest ring nucleases are widespread (23,24,27,30) and most probably essential if type III CRISPR systems are not functioning in defence by abortive infection (22). The genomic context of the *can2* gene suggests that ring nuclease duty is 'outsourced' to dedicated enzymes such as Crn2 and the putative ring nuclease Csx16 (Figure 1).

### Can2 provides immunity against MGE *in vivo*

To investigate the capability of Can2 to confer immunity against MGE *in vivo*, we utilised a recombinant type III CRISPR system from *Mycobacterium tuberculosis* expressed in *E. coli* (15). We combined plasmid pCsm1-5-ΔCsm6 containing the interference complex module Csm1-5 and plasmid pCRISPR\_TetR containing the tetracycline-resistance gene-targeting spacer (TetR targeting spacer) in *E. coli* C43 (DE3) cells, as described in the Methods and previously (15,30). This recombinant CRISPR system was previously confirmed as functional and able to synthesise a range of cyclic oligonucleotides, including cA<sub>3-6</sub>, in the presence of target RNA (15,30). The system allows cA<sub>6</sub> or cA<sub>4</sub> dependent downstream effectors to be incorporated and provide effective immunity against a plasmid transformation challenge. We have shown previously that the HD nuclease domain of *M. tuberculosis* Csm is not capable of providing immunity and has little or no activity *in vitro* (15,30). Therefore, we constructed the plasmid pRAT\_TsuCan2 which harbours the *can2* gene from *T. sulfidophilus* (Tsu, chosen as it is a mesophile) and a tetracycline-resistance gene containing a match to the spacer on pCRISPR\_TetR.

The *E. coli* cells containing pCsm1-5-ΔCsm6 and pCRISPR\_TetR were transformed with pRAT\_TsuCan2. If the type III interference complex detects cognate mRNA from the TetR locus, the cyclase domain will be activated to generate cA<sub>4</sub>. A 10-fold dilution series of the transformation mixture was applied to tetracycline selective plates to determine the number of viable transformants (Figure 3A). Negative control strains included were pRAT without TsuCan2

(No Can2); a variant of Cas10 which cannot produce cOA (Cyclase variant); and crRNA where the TetR targeting spacer was replaced with a spacer targeting the pUC19 multiple cloning site (No targeting). Previous studies demonstrated that the *M. tuberculosis* type III-A CRISPR system requires an ancillary nuclease to provide immunity *in vivo* (15). Compared to the negative controls, three orders of magnitude fewer transformants were observed for cells expressing wild-type TsuCan2 (Figure 3A). Thus, in the presence of cA<sub>4</sub>, Can2 provides effective immunity against incoming MGE, similar to the previously characterised Csx1 effector (15).

The plasmid challenge assay cannot discriminate between plasmid clearance and cell death, due to the requirement of tetracycline resistance for growth. We therefore developed a viral infection challenge assay using the temperate bacteriophage P1 (44). We constructed another plasmid, pCRISPR\_Lpa, which contains a spacer targeting the *lpa* gene of bacteriophage P1. Plasmids pCsm1-5-ΔCsm6, pCRISPR\_Lpa and pRAT\_TsuCan2 were co-transformed into *E. coli* C43 (DE3) cells. The cells were grown in LB broth in a 96-well plate with shaking at 37°C and infected with phage P1 at a multiplicity of infection (MOI) of ~1. Cell growth was monitored by measuring the optical density at a wavelength of 595 nm (OD<sub>595</sub>) (Figure 3B). The control culture (purple) was not infected with the phage and thus grew normally, providing a standard growth curve for the experiment. Cells with defence based on wild-type Can2 (orange) were not affected by phage infection, growing similarly to the control culture. In contrast, a strain where the Lpa-targeting spacer was missing (black) was highly susceptible to phage infection, as was a strain lacking cyclase activity (green), and a strain harbouring the inactive E302A/K304A Can2 variant (grey). The OD<sub>595</sub> reading of each strain after 4 h and 10 h growth was quantified and is shown in Figure 3C. No significant difference was observed between control cells and cells expressing wild-type Can2 (*P*-values > 0.05), whereas the growth of other strains was significantly reduced compared to the control culture at both 4 h and 10 h (*P*-values < 1E-05). These results show that immunity depends on a targeting crRNA matching the phage, synthesis of cA<sub>4</sub> by the cyclase, and the nuclease activity of the Can2 effector.

### Structural analysis of Can2

SthCan2, with selenomethionine incorporated for phasing, was co-crystallised with cA<sub>4</sub>. Diffraction data were collected to 2.02 Å resolution at Diamond Light Source, and the data were processed, scaled, phased from the selenium atoms, and the initial model built using their automated pipeline. Subsequent rounds of automated and manual refinement gave a final *R*<sub>work</sub> of 24% and *R*<sub>free</sub> of 29%. There are four protein molecules in the asymmetric unit, which form two dimers each bound to a molecule of cA<sub>4</sub>. The protein chain can be traced from residue 3 to 366, although there is variation between protein molecules; some miss residues at the N-terminus and/or three different loop regions (centred around residues 160, 222 and/or 300). Efforts were made to crystallise apo SthCan2, but unfortunately no crystals were forthcoming.

Can2 has two distinct domains, linked by a 15-residue highly flexible loop (Figure 4A, B). At the N-terminus there is a CARF domain (residues 3–151) and at the C-terminus a nuclease domain (residues 166–366). The CARF domain displays the canonical Rossman fold, which is highly structurally conserved with Can1 (PDB: 6SCE; RMSD of 2.1 Å over 137 C $\alpha$  atoms for Can2 monomer/RMSD of 2.6 Å over 256 C $\alpha$  atoms for Can2 dimer; Figure 5A) and VC1899 (PDB:1XMX; RMSD of 1.7 Å over 141 C $\alpha$  atoms; Supplementary Figure S5A). The nuclease domain is typical of the PD-D/ExK metal-dependent nuclease family, which comprises a central core of six  $\beta$ -strands flanked by six  $\alpha$ -helices. The nuclease domain of Can2 is highly conserved with VC1899 (RMSD of 2.5 Å over 186 C $\alpha$  atoms), but slightly less so with Can1 (RMSD of 3.2 Å over 139 C $\alpha$  atoms; Figure 5B). This is due to a motif additional to the core nuclease fold present in Can2 and VC1899 comprising four  $\alpha$ -helices flanking two antiparallel  $\beta$ -strands; in Can 1 a helix-turn-helix motif is in a near equivalent position.

#### cA<sub>4</sub> recognition by Can2

Unambiguous electron density in the  $F_{\text{obs}} - F_{\text{calc}}$  map at  $3\sigma$  at the interface between the CARF domains in the dimer of Can2 corresponded to a molecule of cA<sub>4</sub> (Supplementary Figure S6) enclosed in the binding site (Figure 4B). The cA<sub>4</sub> molecule makes symmetrical interactions with each Can2 monomer, which differs from the asymmetric interactions made between Can1 and cA<sub>4</sub>. All interactions made between Can2 and cA<sub>4</sub> are solely from the CARF domains (Figures 5A, 6A). Hydrogen bonds form between cA<sub>4</sub> and main chain residues of Asp20, His21, and Lys99 and side chain residues of Ser19, Asp20, Thr42, Lys99, Tyr118 and Ser121 in both molecules of the Can2 dimer. Superposition of the cA<sub>4</sub> molecules from the complexes with Can1 and Can2 (RMSD of 3.1 Å over 88 atoms; Figure 5C) show the majority of the atoms are in a similar position. The most significant difference is one of the adenosine moieties (A1, Figure 5C). It was noted that in Can1, the adenine base of A1 adopted an axial position at the anomeric carbon of the ribose, which likely arose from a  $\pi$ - $\pi$  stacking interaction with a nearby tryptophan residue. In Can2, which lacks this key tryptophan residue, the adenosine in the equivalent position adopts a similar conformation to the others in the cA<sub>4</sub> molecule.

#### Structural comparisons of cA<sub>4</sub> binding in Can2 with Can1 and VC1899

Although the overall sequence identity between Can2 and Can1 is low, there is a high level of structural conservation (Supplementary Figure S7A). Closer examination of the binding site interactions made between the CARF domains of Can1 and Can2 with cA<sub>4</sub> highlighted the residues that are likely to be key from an evolutionary standpoint. The interactions formed by just four residues were conserved between the two structures (Figure 6, Supplementary Figure S8A, B); these are (Can2 numbering) Ser19, Thr42, Lys99, and Tyr118. Ser19 and Tyr118 each form a single hydrogen bond with a (different) phosphate group, and Thr42


with an adenine base. The conserved lysine (Lys99) in both Can1 and Can2 forms hydrogen bonds, via both its terminal and main chain nitrogen atoms, with the two non-bonded oxygen atom/hydroxyl group in a single phosphate moiety. What is striking about these four residues is they interact with the same ‘side’ of the cA<sub>4</sub> molecule (A3 and A4 in Figure 6), even though three of the residues originate from one of the Can2 monomers/second CARF domain of Can1, and one residue from the other Can2 monomer/first CARF domain of Can1. Sequence comparison of Can2 with Can1 shows the C-terminal CARF and nuclease domains of the latter have the highest similarity to Can2, which is consistent with the conservation of the interactions observed. Therefore, it is likely that the C-terminal ‘half’ of Can1 and Can2 are evolutionarily related, and the N-terminal ‘half’ of Can1 arose from gene duplication. This may explain why the Can1 nuclease-like domain lacks the canonical nuclease active site residues, but it is intriguing why the first CARF domain of Can1 has evolved to interact differently with the other ‘half’ of cA<sub>4</sub> (ie. A1 and A2 in Figure 6).

The highest overall sequence homology and structure conservation for Can2 is with VC1899. Comparison of the cA<sub>4</sub> binding site (Supplementary Figure S8A, C), however, reveals there is no conservation of residues in VC1899 that interact with cA<sub>4</sub> in Can2. The four residues that were observed to be conserved between Can1 and Can2, both in sequence and structure, Ser19, Thr42, Lys99 and Tyr118, are Asp9, Asp34, Arg96 and Val115, respectively in VC1899. Other residues in VC1899 surrounding the modelled cA<sub>4</sub> molecule are Gln10, Asp11, Arg14, Pro118, Leu95 and Gln334. The sole example of conservation of residue properties is Arg96, which is equivalent to Lys99 in Can2. The rest of the predicted binding site residues show different properties to their equivalent residues in Can2, with several possessing a negative charge (Asp9, Asp11, Asp34) or are hydrophobic (Val115, Pro118, Leu95). These properties, especially the residues with a negative charge, would not be conducive to interacting with a negatively charged cA<sub>4</sub> molecule, and contrasts with the Can2 binding site where all residues are polar and capable of forming hydrogen bond interactions with cA<sub>4</sub>. The nature of the binding site, which would not support binding of cA<sub>4</sub> without a high energetic barrier, therefore supports the biochemical studies which show that cA<sub>4</sub> is not capable of activating nuclease activity in VC1899.


#### Recognition of DNA by the nuclease domain

The structure of Can2 bound to cA<sub>4</sub> represents the active state of the enzyme. To understand the likely mechanism of the nuclease, and in particular the recognition of nucleic acid substrates, we investigated structural similarities between Can2 and other PD-ExK family nucleases. The closest structural homologue to the nuclease domain of Can2 with dsDNA bound was the mismatch repair enzyme EndoMS (45), a dimeric enzyme that detects mismatches in dsDNA and introduces nicks in both DNA strands, resulting in a double strand break. The nuclease domains of Can2 and EndoMS align with an RMSD of 4.4 Å over 108 C $\alpha$  atoms, and the secondary structure elements in the core of the nuclease and the active site residues superimpose well







**Figure 4.** Structure of Can2 bound to cA<sub>4</sub> activator. (A) Two views of the Can2 dimer in cartoon representation. The CARF domain is shown in cyan and the nuclease domain in blue. A molecule of cA<sub>4</sub> is bound across the CARF dimer, which is shown as spheres (carbon in yellow, oxygen in red, nitrogen in blue, phosphate in magenta). (B) Surface representation of Can2 dimer with the same colouring as (A).



**Figure 5.** Structural comparison of Can2 with Can1. (A) Superimposition of CARF domain dimer from Can2 (cyan) bound to cA<sub>4</sub> (yellow) with the CARF domains of Can1 bound to cA<sub>4</sub> (PDB: 6SCE) (pink). The Can2 CARF domain dimer superimposes with the Can1 CARF domains with an RMSD of 2.6 Å over 256 C $\alpha$  atoms. (B) Superimposition of nuclease domain from Can2 (blue) and Can1 (pink) (RMSD of 3.2 Å over 139 C $\alpha$  atoms). (C) Superimposition cA<sub>4</sub> molecules bound to Can2 (yellow) and Can1 (pink) shown in stick representation (carbon in yellow/pink, oxygen in red, nitrogen in blue, phosphate in magenta; RMSD 3.1 Å over 88 atoms). Each AMP is numbered (A1-A4).



**Figure 6.** Structural comparison of cA<sub>4</sub> bound to Can2. Divergent stereo representation of cA<sub>4</sub> (in stick representation; carbon in yellow, nitrogen in blue, oxygen in red; phosphorus in orange) in complex with the Can2 CARF domain dimer (in stick representation; each monomer in the dimer is coloured green or magenta). Each AMP is numbered (A1-A4). The dotted lines represent hydrogen bond interactions. The residue labels in bold indicate there is a conserved interaction between cA<sub>4</sub> in both Can 1 and Can2.



**Figure 7.** Predicted ternary complex of Can2 and  $cA_4$ , with dsDNA modelled. (A) Superimposition of the nuclease domain of Can2 (blue) with the nuclease domain of EndoMS in complex with dsDNA (PDB: 5GKE) in cartoon representation (green) (RMSD 4.4 Å over 108 C $\alpha$  atoms). (B) Close-up view of panel A. The active site residues of Can2 (Glu276 and Asp278) are shown as blue sticks, and the active sites residues (Glu156 and D158A mutant) and metal ion ( $Mg^{2+}$ ) of EndoMS shown as green sticks and sphere respectively.

(Figure 7A, B; Supplementary Figure S9). A similar comparison with the restriction endonuclease *AgeI* (46) confirms the nuclease superfamily fold and conservation of key catalytic residues in a suitable position to engage with DNA (Supplementary Figure S10). These comparisons help to define the site of nucleic acid binding in Can2. The dsDNA substrate from EndoMS in the superimposed structures sits in the cleft between the two Can2 nuclease domains (Figure 7). There appears to be room in this cleft to accommodate canonical dsDNA if it is assumed that the flexible loop (Thr294–Asn304) can move to accommodate the DNA, allowing nicking by Can2. Clearly ssRNA as a smaller molecule could also be accommodated in this cleft. This analysis suggests that the mechanism of  $cA_4$ -dependent activation is likely to be via allosteric structural reorganisation that opens the cleft, allowing access to DNA and RNA substrates.

## DISCUSSION

Here we show that Can2, a widely distributed CARF-superfamily protein associated with type III CRISPR systems, is a  $cA_4$ -activated DNA nickase and RNase that can provide immunity against bacteriophage *in vivo*. Can2 is a member of the DUF1887 protein family, whose founding member is the VC1899 protein from *V. cholerae* – one of the first CARF family proteins to be studied structurally (PDB: 1XMX), although the structure has never been described in a publication. VC1899 has remained uncharacterised, and notably is an orphan CARF protein that is not associated with a type III CRISPR system. Our biochemical studies indicate that it has weak residual RNase activity that is not regulated by  $cA_4$ , and structural studies indicate that the site where  $cA_4$  would bind (based on conservation with Can2) is largely composed of negatively charged and hydrophobic residues that would not be conducive to binding of a negatively charged  $cA_4$  molecule. Therefore, VC1899 may represent a degenerate defence enzyme that has been ‘cast adrift’ from a CRISPR system and does not retain its original function. In contrast, the Tsu and Sth Can2 orthologues are robust metal and  $cA_4$ -dependent nucleases. Like Can1, the primary role of Can2 may be to function as a nickase in

infected cells, generating single-strand ligatable nicks in supercoiled DNA to slow down phage replication (19). Structural comparisons with the EndoMS nuclease suggest that Can2 is activated upon binding  $cA_4$ , to enable binding of nucleic acid substrates between the two nuclease domains in a position ideal for catalysis.

Whilst there are obvious differences in the  $cA_4$  binding site between Can2 and VC1899, the nuclease domain is conserved, and VC1899 has the key nuclease active site residues (Glu276/Asp278 in Can2 and Glu291/Asp293 in VC1899). Although VC1899 is not active *in vitro*, structural comparison with Can2 is still relevant as it may highlight differences in the active ( $cA_4$  bound) and inactive (no  $cA_4$  bound) states. Superposition of Can2 with VC1899 has an RMSD of 2.7 Å over 380 C $\alpha$  atoms, which is higher than just the CARF domain (RMSD of 1.7 Å over 141 C $\alpha$  atoms) or just the nuclease domain (RMSD of 2.5 Å over 186 C $\alpha$  atoms), suggesting there is a difference in the orientation of the domains in relation to each other. This is indeed observed (Supplementary Figure S5B), and it is clear these differences arise in the nuclease domains rather than the CARF domains which show high structural conservation (Supplementary Figure S5A). There are differences in the position of equivalent secondary structure elements throughout the nuclease domain, with the largest being an  $\alpha$ -helix that faces into the DNA binding site. There is an approximate  $\sim 10$  Å difference in the position of the helix, where Can2 ( $cA_4$  bound) has the helix from each monomer in the dimer closer than in VC1899 (no  $cA_4$  bound). This causes a change in an approximate helix-to-helix distance of  $\sim 45$  Å in VC1899 to  $\sim 25$  Å in Can2 (Supplementary Figure S5B). In addition, a loop originating from a different part of the nuclease domain appears to extend further into the DNA binding region in Can2 than VC1899; the caveat being this loop is partially disordered in both structures and so is evidently flexible. These differences in the position of elements of the nuclease domains likely indicate the state prior to binding of DNA, whereby Can2 has been activated and VC1899 has not. It can therefore be hypothesized that the helix and loop that face into the DNA binding site likely play a role in DNA binding and orientating the substrate to the nearby nuclease active site.

Whilst comparison of Can2 and VC1899 can suggest the effect of cA<sub>4</sub> binding upon rearrangements in the nuclease domain that enable DNA binding, it is more difficult to predict (a) how cA<sub>4</sub> itself binds as it is likely to require significant structural rearrangements and (b) how binding of cA<sub>4</sub> leads to activation of the nuclease domain. Small angle X-ray scattering experiments and temperature factor analysis performed with Can1 suggested that the nuclease and nuclease-like domains were more mobile than the CARF domains (19). This led to a model whereby Can1 was sampling between open and closed states, and cA<sub>4</sub> could bind when in the open state. Upon binding, the protein would be stabilized and ‘lock’ Can1 in the closed state. Such a model would also explain why it was difficult to get diffracting crystals for both apo Can1 and Can2. However, Can1 is unusual in that it has two CARF domains and both nuclease/nuclease-like domains in a single polypeptide, whereby Can2 is a dimer with just one CARF and nuclease domain. The question therefore remains whether the dimer is pre-formed based on interactions within the CARF domain and samples between an open and closed state as postulated for Can1, or cA<sub>4</sub> binds to a monomer of Can2, which enables the dimer to form.

One interesting observation is the difference in the overall size of Can2 relative to Can1; whilst Can1 only has ~100 residues less than the Can2 dimer, the overall dimensions of the structure indicate it is much more compressed, with the four domains tightly packed (Supplementary Figure S7B, C). Although difficult to measure with precision, Can2 is ~15–20 Å larger if measured from the top of the nuclease domain to the bottom of the CARF domain. The cA<sub>4</sub> molecule is enclosed in Can2, meaning protein residues would need to move to allow it to bind, however, there is more void space surrounding the cA<sub>4</sub> molecule in Can2 than Can1. Given this relative greater distance between the cA<sub>4</sub> molecule and the nuclease domain, it makes it more difficult to ascertain which residues in the nuclease domain may be involved in ‘sensing’ the binding of cA<sub>4</sub> leading to activation of the nuclease domain. In Can1 there is a direct interaction between Gly550, which originated from the nuclease domain, with the cA<sub>4</sub>. In addition, Gln222, from the nuclease-like domain, sits above the centre of cA<sub>4</sub> and makes two water-mediated hydrogen bond interactions with phosphate groups on opposite sides of the ring. There are no residues equivalent to these in Can2, which is a consequence of the less dense packing, and so there must be further subtle rearrangements of residues to enable this activation message to be transmitted.

The observation that SthCan2 can degrade both DNA and RNA is unusual but not unprecedented. Although the preferred cation is Mn<sup>2+</sup>, RNase activity is also supported by Mg<sup>2+</sup> at a lower level. Other nucleases with this dual specificity include the tomato multifunctional nuclease TBN1, which is a member of the phospholipase C/P1 nuclease family (47), and *Serratia marcescens* endonuclease of the EndoG family (48). The latter has been used to design a synthetic conditional suicide system in *E. coli* (49), analogous to the altruistic suicide seen in abortive infection. The observation that TsuCan2 primarily degrades RNA substrates *in vitro*, with only weak DNA nicking activity observed at high temperatures, suggests that this enzyme may primar-

ily function as a cA<sub>4</sub>-activated non-specific RNA degrading nuclease, analogous to the Csm6/Csx1 family of CRISPR ancillary nucleases. The rate of RNA cleavage, which exceeds 1 min<sup>-1</sup> under single turnover conditions, is comparable with rate constants observed for Csm6/Csx1 family enzymes (12,22).

The demonstration that Can2 can be ‘hooked up’ with the *M. tuberculosis* type III-A CRISPR system, which normally functions via the cA<sub>6</sub>-activated Csm6 ribonuclease (15), emphasises the power and flexibility of type III cOA signalling, where the cyclic nucleotide second messenger and effector nuclease can be swapped without losing immunity. Frequently, multiple effectors are observed associated with one type III system (for example, the NucC and Can2 effectors present in *M. ishizawai*, shown in Figure 1). This flexibility may be another reflection of the pressure imposed by phage anti-CRISPRs (Acrcs) – as for example a cA<sub>4</sub>-specific Acr could knock out Can2 or Csx1, but not Csm6 or NucC. It is notable that Can2 provides immunity from phage P1 infection, without causing a noticeable growth defect in host cells. This suggests that defence based on Can2 operates by slowing down phage replication, rather than an abortive infection mechanism. The ligatable nicks generated by SthCan2 may therefore preferentially target replicating phage DNA, as suggested for the Can1 enzyme (19). The observation of variable nickase activity in the Can2 orthologues may indicate that RNA cleavage is the predominant immune activity *in vivo* – placing Can2 closer to the Csx1/Csm6 family than the Can1 family. Further work is required to ascertain whether Can2 can provide similar levels of immunity against a broader range of bacteriophages, including RNA phages.

While this paper was in the final stages of revision, an independent study of the Can2 enzyme from *Treponema succinifaciens* was published. The enzyme, which was named Card1, has similar properties as a manganese and cA<sub>4</sub> dependent relaxed specificity nuclease (50).

## DATA AVAILABILITY

The molecular coordinates for the Can2 protein structure are available in the Protein Databank under accession code 7BDV.

## SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

## ACKNOWLEDGEMENTS

*Author contributions:* W.Z. designed biochemical experiments, carried out experiments and analysed data in consultation with M.F.W. S.McM performed preliminary crystallisation experiments and S.McQ. crystallised the protein, solved and analysed the structure in consultation with T.M.G. S.Gra. cloned and purified proteins. S.Gru. carried out the plasmid and phage challenge assays along with W.Z. T.M.G and M.F.W. conceptualised the project, obtained funding, carried out formal analysis and prepared the original draft of the manuscript. All authors contributed to writing, review and editing.

## FUNDING

Biotechnology and Biological Sciences Research Council [BB/S000313/1 to M.F.W., BB/T004789/1 to M.F.W. and T.M.G.]; Wellcome Trust Institutional Strategic Support Funding [204821/Z/16/Z to M.F.W. and T.M.G.]; China Scholarship Council [201703780015 to W.Z.]. Funding for open access charge: RCUK block grant.

*Conflict of interest statement.* None declared.

## REFERENCES

- Barrangou, R. and Marraffini, L.A. (2014) CRISPR-Cas systems: prokaryotes upgrade to adaptive immunity. *Mol. Cell*, **54**, 234–244.
- Makarova, K.S., Wolf, Y.I., Alkhnbashi, O.S., Costa, F., Shah, S.A., Saunders, S.J., Barrangou, R., Brouns, S.J., Charpentier, E., Haft, D.H. *et al.* (2015) An updated evolutionary classification of CRISPR-Cas systems. *Nat. Rev. Microbiol.*, **13**, 722–736.
- Makarova, K.S., Wolf, Y.I., Iranzo, J., Shmakov, S.A., Alkhnbashi, O.S., Brouns, S.J., Charpentier, E., Cheng, D., Haft, D.H., Horvath, P. *et al.* (2020) Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants. *Nat. Rev. Microbiol.*, **18**, 67–83.
- Hale, C.R., Zhao, P., Olson, S., Duff, M.O., Graveley, B.R., Wells, L., Terns, R.M. and Terns, M.P. (2009) RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex. *Cell*, **139**, 945–956.
- Samai, P., Pyenson, N., Jiang, W., Goldberg, G.W., Hatoum-Aslan, A. and Marraffini, L.A. (2015) Co-transcriptional DNA and RNA cleavage during type III CRISPR-Cas immunity. *Cell*, **161**, 1164–1174.
- Tamulaitis, G., Kazlauskienė, M., Manakova, E., Venclovas, C., Nwokeoji, A.O., Dickman, M.J., Horvath, P. and Siksnys, V. (2014) Programmable RNA shredding by the type III-A CRISPR-Cas system of *Streptococcus thermophilus*. *Mol. Cell*, **56**, 506–517.
- Kazlauskienė, M., Tamulaitis, G., Kostiuk, G., Venclovas, C. and Siksnys, V. (2016) Spatiotemporal control of type III-A CRISPR-Cas immunity: coupling DNA degradation with the target RNA recognition. *Mol. Cell*, **62**, 295–306.
- Estrella, M.A., Kuo, F.T. and Bailey, S. (2016) RNA-activated DNA cleavage by the Type III-B CRISPR-Cas effector complex. *Genes Dev.*, **30**, 460–470.
- Elmore, J.R., Sheppard, N.F., Ramia, N., Deighan, T., Li, H., Terns, R.M. and Terns, M.P. (2016) Bipartite recognition of target RNAs activates DNA cleavage by the Type III-B CRISPR-Cas system. *Genes Dev.*, **30**, 447–459.
- Rouillon, C., Athukoralage, J.S., Graham, S., Gruschow, S. and White, M.F. (2018) Control of cyclic oligoadenylate synthesis in a type III CRISPR system. *eLife*, **7**, e36734.
- Kazlauskienė, M., Kostiuk, G., Venclovas, C., Tamulaitis, G. and Siksnys, V. (2017) A cyclic oligonucleotide signaling pathway in type III CRISPR-Cas systems. *Science*, **357**, 605–609.
- Niewoehner, O., Garcia-Doval, C., Rostol, J.T., Berk, C., Schwede, F., Bigler, L., Hall, J., Marraffini, L.A. and Jinek, M. (2017) Type III CRISPR-Cas systems produce cyclic oligoadenylate second messengers. *Nature*, **548**, 543–548.
- Lin, J., Feng, M., Zhang, H. and She, Q. (2020) Characterization of a novel type III CRISPR-Cas effector provides new insights into the allosteric activation and suppression of the Cas10 DNase. *Cell Discov.*, **6**, 29.
- Makarova, K.S. and Koonin, E.V. (2015) Annotation and classification of CRISPR-Cas systems. *Methods Mol. Biol.*, **1311**, 47–75.
- Gruschow, S., Athukoralage, J.S., Graham, S., Hoogeboom, T. and White, M.F. (2019) Cyclic oligoadenylate signalling mediates *Mycobacterium tuberculosis* CRISPR defence. *Nucleic Acids Res.*, **47**, 9259–9270.
- Molina, R., Stella, S., Feng, M., Sofos, N., Jauniskis, V., Pozdnyakova, I., Lopez-Mendez, B., She, Q. and Montoya, G. (2019) Structure of Csx1-cOA4 complex reveals the basis of RNA decay in Type III-B CRISPR-Cas. *Nat. Commun.*, **10**, 4302.
- Jia, N., Jones, R., Yang, G., Ouerfelli, O. and Patel, D.J. (2019) CRISPR-Cas III-A Csm6 CARF domain is a ring nuclease triggering stepwise cA4 cleavage with ApA>p formation terminating RNase activity. *Mol. Cell*, **75**, 944–956.
- Garcia-Doval, C., Schwede, F., Berk, C., Rostol, J.T., Niewoehner, O., Tejero, O., Hall, J., Marraffini, L.A. and Jinek, M. (2020) Activation and self-inactivation mechanisms of the cyclic oligoadenylate-dependent CRISPR ribonuclease Csm6. *Nat. Commun.*, **11**, 1596.
- McMahon, S.A., Zhu, W., Graham, S., Rambo, R., White, M.F. and Gloster, T.M. (2020) Structure and mechanism of a Type III CRISPR defence DNA nuclease activated by cyclic oligoadenylate. *Nat. Commun.*, **11**, 500.
- Lau, R.K., Ye, Q., Birkholz, E.A., Berg, K.R., Patel, L., Mathews, I.T., Watrous, J.D., Ego, K., Whiteley, A.T., Lowey, B. *et al.* (2020) Structure and mechanism of a cyclic trinucleotide-activated bacterial endonuclease mediating bacteriophage immunity. *Mol. Cell*, **77**, 723–733.
- Cohen, D., Melamed, S., Millman, A., Shulman, G., Oppenheimer-Shaanan, Y., Kacen, A., Doron, S., Amitai, G. and Sorek, R. (2019) Cyclic GMP-AMP signalling protects bacteria against viral infection. *Nature*, **574**, 691–695.
- Athukoralage, J.S., Graham, S., Rouillon, C., Gruschow, S., Czekster, C.M. and White, M.F. (2020) The dynamic interplay of host and viral enzymes in type III CRISPR-mediated cyclic nucleotide signalling. *eLife*, **9**, e55852.
- Athukoralage, J.S., Rouillon, C., Graham, S., Gruschow, S. and White, M.F. (2018) Ring nucleases deactivate Type III CRISPR ribonucleases by degrading cyclic oligoadenylate. *Nature*, **562**, 277–280.
- Athukoralage, J.S., McQuarrie, S., Gruschow, S., Graham, S., Gloster, T.M. and White, M.F. (2020) Tetramerisation of the CRISPR ring nuclease Crn3/Csx3 facilitates cyclic oligoadenylate cleavage. *eLife*, **9**, e57627.
- Athukoralage, J.S., Graham, S., Gruschow, S., Rouillon, C. and White, M.F. (2019) A type III CRISPR ancillary ribonuclease degrades its cyclic oligoadenylate activator. *J. Mol. Biol.*, **431**, 2894–2899.
- Makarova, K.S., Anantharaman, V., Grishin, N.V., Koonin, E.V. and Aravind, L. (2014) CARF and WYL domains: ligand-binding regulators of prokaryotic defense systems. *Frontiers in genetics*, **5**, 102.
- Samolygo, A., Athukoralage, J.S., Graham, S. and White, M.F. (2020) Fuse to defuse: a self-limiting ribonuclease-ring nuclease fusion for type III CRISPR defence. *Nucleic Acids Res.*, **48**, 6149–6156.
- Makarova, K.S., Timinskas, A., Wolf, Y.I., Gussow, A.B., Siksnys, V., Venclovas, C. and Koonin, E.V. (2020) Evolutionary and functional classification of the CARF domain superfamily, key sensors in prokaryotic antiviral defense. *Nucleic Acids Res.*, **48**, 8828–8847.
- Rouillon, C., Athukoralage, J.S., Graham, S., Gruschow, S. and White, M.F. (2019) Investigation of the cyclic oligoadenylate signalling pathway of type III CRISPR systems. *Methods Enzymol.*, **616**, 191–218.
- Athukoralage, J.S., McMahon, S.A., Zhang, C., Gruschow, S., Graham, S., Krupovic, M., Whitaker, R.J., Gloster, T.M. and White, M.F. (2020) An anti-CRISPR viral ring nuclease subverts type III CRISPR immunity. *Nature*, **577**, 572–575.
- Winter, G. (2010) xia2: an expert system for macromolecular crystallography data reduction. *J. Appl. Crystallogr.*, **43**, 186–190.
- Kabsch, W. (2010) Xds. *Acta Crystallogr. D. Biol. Crystallogr.*, **66**, 125–132.
- Evans, P. (2006) Scaling and assessment of data quality. *Acta Crystallogr. D. Biol. Crystallogr.*, **62**, 72–82.
- Sikharulidze, I., Winter, G. and Hall, D.R. (2016) Big EP: automated structure solution pipeline deployment at Diamond Light Source. *Acta Crystallogr. A: Found. Adv.*, **72**, S193.
- Sheldrick, G.M. (2008) A short history of SHELX. *Acta Crystallogr. A*, **64**, 112–122.
- Skubak, P. and Pannu, N.S. (2011) Reduction of density-modification bias by beta correction. *Acta Crystallogr. D. Biol. Crystallogr.*, **67**, 345–354.
- Murshudov, G.N., Skubak, P., Lebedev, A.A., Pannu, N.S., Steiner, R.A., Nicholls, R.A., Winn, M.D., Long, F. and Vagin, A.A. (2011) REFMAC5 for the refinement of macromolecular crystal structures. *Acta Crystallogr. D-Struct. Biol.*, **67**, 355–367.
- Emsley, P. and Cowtan, K. (2004) Coot: model-building tools for molecular graphics. *Acta Crystallogr. D-Biol. Crystallogr.*, **60**, 2126–2132.

39. Lebedev,A.A., Young,P., Isupov,M.N., Moroz,O.V., Vagin,A.A. and Murshudov,G.N. (2012) JLigand: a graphical tool for the CCP4 template-restraint library. *Acta Crystallogr. D-Struct. Biol.*, **68**, 431–440.
40. McNicholas,S., Potterton,E., Wilson,K.S. and Noble,M.E. (2011) Presenting your structures: the CCP4mg molecular-graphics software. *Acta Crystallogr. D, Biol. Crystallogr.*, **67**, 386–394.
41. Joosten,R.P., Long,F., Murshudov,G.N. and Perrakis,A. (2014) The PDB\_REDO server for macromolecular structure model optimization. *Iucrj*, **1**, 213–220.
42. Chen,V.B., Arendall,W.B. 3rd, Headd,J.J., Keedy,D.A., Immormino,R.M., Kapral,G.J., Murray,L.W., Richardson,J.S. and Richardson,D.C. (2010) MolProbity: all-atom structure validation for macromolecular crystallography. *Acta Crystallogr. D, Biol. Crystallogr.*, **66**, 12–21.
43. Holm,L. (2020) DALI and the persistence of protein shape. *Protein Sci.*, **29**, 128–140.
44. Lobočka,M.B., Rose,D.J., Plunkett,G. 3rd, Rusin,M., Samojedny,A., Lehnerr,H., Yarmolinsky,M.B. and Blattner,F.R. (2004) Genome of bacteriophage P1. *J. Bacteriol.*, **186**, 7032–7068.
45. Nakae,S., Hijikata,A., Tsuji,T., Yonezawa,K., Kouyama,K.I., Mayanagi,K., Ishino,S., Ishino,Y. and Shirai,T. (2016) Structure of the EndoMS-DNA complex as mismatch restriction endonuclease. *Structure*, **24**, 1960–1971.
46. Tamulaitiene,G., Jovaisaite,V., Tamulaitis,G., Songailiene,I., Manakova,E., Zaremba,M., Grazulis,S., Xu,S.Y. and Siksnys,V. (2017) Restriction endonuclease AgeI is a monomer which dimerizes to cleave DNA. *Nucleic Acids Res.*, **45**, 3547–3558.
47. Podzimek,T., Matousek,J., Lipovova,P., Pouckova,P., Spiwok,V. and Santrucek,J. (2011) Biochemical properties of three plant nucleases with anticancer potential. *Plant Sci.*, **180**, 343–351.
48. Friedhoff,P., Gimadudinow,O. and Pingoud,A. (1994) Identification of catalytically relevant amino acids of the extracellular *Serratia marcescens* endonuclease by alignment-guided mutagenesis. *Nucleic Acids Res.*, **22**, 3280–3287.
49. Ahrenholtz,I., Lorenz,M.G. and Wackernagel,W. (1994) A conditional suicide system in *Escherichia coli* based on the intracellular degradation of DNA. *Appl. Environ. Microbiol.*, **60**, 3746–3751.
50. Rostol,J.T., Xie,W., Kuryavii,V., Maguin,P., Kao,K., From,R., Patel,D.J. and Marraffini,L.A. (2021) The Card1 nuclease provides defence during type-III CRISPR immunity. *Nature*, doi:10.1038/s41586-41021-03206-x.